Amendment No. 3 to Schedule 13D for ATAI Life Sciences N.V.

This Amendment No. 3 to Schedule 13D, filed on October 20, 2025, provides updated information regarding the beneficial ownership of Ordinary Shares of ATAI Life Sciences N.V. by Apeiron Investment Group Ltd., Apeiron Presight Capital Fund II, L.P., Presight Capital Management I, L.L.C., Fabian Hansen, and Christian Angermayer. As of the date of this amendment, the reporting persons collectively own 55,211,716 Ordinary Shares, representing approximately 23.4% of the voting rights. Christian Angermayer may be deemed to beneficially own an additional 1,339,663 Ordinary Shares underlying vested options. The amendment also includes details of a lock-up agreement entered into by Apeiron with Jefferies LLC, restricting the sale or transfer of Ordinary Shares for 90 days following the pricing of a recent offering.